Immunome
Recapitalization and $20.5 million investment

Immunome is an immuno-oncology company focused on identifying novel cancer immunotherapies utilizing a patented process to immortalize human b-cells

  • The company utilizes high-content screening and leverages the immune repertoire of “exceptional responders” to generate large libraries of human hybridomas and utilizes high-throughput screening to interrogate huge libraries against deep tumor antigen sources for purpose of Ab identification

  • $20.5 million in total new equity invested with an additional $3.5 million committed upon the achievement of specified milestones

Led by Michael Morin
  • Former head of immunology and oncology drug discovery at Pfizer

  • Introduced to Mike Morin through the diligence process and retained as CEO

Hold two board seats
  • Mike Rapoport is non-executive chairman

  • Phil Wagenheim is a board member and former interim President and CEO.

  • Broadband Capital identified and delivered the key management addition of Purnanand Sarma as President and CEO – Formerly President and CEO of Taris Biomedical.

Immunome
Recapitalization and $45.2 million Investment Traditional IPO led by Ladenburg Thalmann

Immunome harnesses the Human Memory B Cell Response To Develop Antibody-Based Therapeutics.

  • Proprietary Discovery Engine

  • Rapid, Unbiased Interrogation of Patient Memory B Cells

  • Applicable Across Multiple Therapeutic Areas

Hold two board seats

  • Michael Rapp is non-executive chairman

  • Phil Wagenheim is a board member and former interim President and CEO

Broadband Capital identified and delivered key management additions:
  • Michael Morin appointed as CEO (2016 – 2019). Former head of immunology and oncology drug discovery at Pfizer

  • Purnanand Sarma as current President and CEO – Formerly President and CEO of Taris Biomedical acquired by Johnson & Johnson in 2019.

Zynerba Pharmaceuticals
Recapitalization and Financing Leading to Successful IPO

Zynerba Pharmaceuticals (NasdaqGM: ZYNE) priced its IPO in August  2015 at $14.00

  • Represented ~3.5x return from BCM led round (October 2014)

  • Jefferies and Piper Jaffray acted as lead underwriters

  • Additional $7 million investment in connection with the IPO

BCM identified the company and provided access to capital

  • The company was a 10 year old startup with debt on its balance sheet, no access to capital and no commercialization expertise

  • $13.2 million financing led by Perceptive Advisors and BCM principals

BCM also identified and retained new management with public company experience and deep expertise in transdermal technology:

  • Armando Anido, former CEO of NuPathe (PATH) and Auxilium (AUXL) joined as Chairman and CEO, Terri Sebree, Donna Gutterman, Suzanne Hanlon and Carol O’Neill, all former senior employees at NuPathe also joined the management team

Held two board seats

  • Phil Wagenheim served as a board member until IPO and acted as interim President and CEO; Michael Rapoport was also a board member

Zynerba Pharmaceuticals
Recapitalization and Financing Traditional IPO led by Jefferies

Next-generation transdermal cannabinoid therapeutics.

Zynerba Pharmaceuticals (NasdaqGM: ZYNE)

BCM identified the company and provided access to capital.

  • The company was a 10 year old startup with debt on its balance sheet, no access to capital and no commercialization expertise

  • $13.2 million financing led by Perceptive Advisors and BCM principals

BCM also identified and retained new management with public company experience and deep expertise in transdermal technology

  • Armando Anido, former CEO of NuPathe (PATH) and Auxilium (AUXL) joined as Chairman and CEO, Terri Sebree, Donna Gutterman, Suzanne Hanlon and Carol O’Neill, all former senior employees at NuPathe also joined the management team

BCM also identified and retained new management with public company experience and deep expertise in transdermal technology:

  • Armando Anido, former CEO of NuPathe (PATH) and Auxilium (AUXL) joined as Chairman and CEO, Terri Sebree, Donna Gutterman, Suzanne Hanlon and Carol O’Neill, all former senior employees at NuPathe also joined the management team

Held two board seats

  • Philip Wagenheim served as a board member until IPO and acted as interim President and CEO

  • Michael Rapp was also a board member

Vroom
BCM Acted as Agent and Principal Providing Founding Capital

Vroom is one of the the largest internet used car retailer, with over $1 billion of revenues

  • Currently led by Paul Hennessy, the former CEO of Priceline.com

BCM provided $7.3 million in founding (Series A) capital

  • Co-investment by BCM principals represented approximately 25% of total capital

  • BCM delivered the lead investor in the $13 million Series B financing round (January 2015)

Vroom went on to raise an additional $346 million

  • Round raised $85 million; led by Catterton and T. Rowe Price

  • Represents 5.0x from Series A investment

  • The most recent completed in December of 2018 where Vroom raised $146,000,000 in a series G funding led by AutoNation.

BCM identified and delivered key management additions Elie Wurtman (Executive Chairman) and Allon Bloch (CEOs)

  • Messrs. Wurtman and Bloch were instrumental in transitioning the company to an online sales platform

Vroom has plans to go public in 2020

Vroom
BCM Acted as Agent and Principal Providing Founding Capital Traditional IPO led by Goldman Sachs

Vroom is one of the largest internet used car retailer, with over $1 billion of revenues

  • Currently led by Paul Hennessy, the former CEO of Priceline.com

BCM provided $7.3 million in founding (Series A) capital

  • Co-investment by BCM principals represented approximately 25% of total capital

  • BCM delivered the lead investor in the $13 million Series B financing round (January 2015)

Vroom went on to raise an additional $770 million privately

  • Various rounds led by Catterton, T. Rowe Price, Durable Capital Partners LP, General Catalyst, AutoNation and Cascade

BCM identified and delivered key management additions
  • Elie Wurtman (Former Executive Chairman) Previous General Partner Benchmark Capital Israel

  • Allon Bloch (Former CEO) Previous CEO at Wix.com

Hydrofarm
Control Buyout of Leading Hydroponics Distributor

Hydrofarm is a U.S.-based distributor, designer and marketer of a comprehensive assortment of specialty indoor gardening supplies.

  • With 5,000+ SKUs, and 1,000+ proprietary SKUs the company offers one of the largest assortments of indoor gardening merchandise in North America

  • The company was founded in 1977 and is based in California with 250+ employees

Broadband Capital co-invested alongside Serruya Private Equity and Hawthorn Equity Partners in connection with a $220 million control buyout transaction

  • Investment vehicles controlled by Broadband Capital invested $25 million, representing ~28% of new equity

  • Principals of Broadband Capital represented ~20% of total investment vehicle equity.

Broadband Capital co-invested alongside Serruya Private Equity, Hawthorn Equity Partners in connection with a $55mm equity financing.

Broadband Capital identified and delivered the key management addition of

  • Terry Fitch as President – Formerly of Coca-Cola Company and Coke Enterprises

  • William Toler as Chairman and CEO – Formerly CEO of AdvancePierre Foods, President of Pinnacle Foods and President and CEO of Hostess Brands

Hydrofarm
Control Buyout of Leading Hydroponics Distributor and Financing Traditional IPO led by JP Morgan

Hydrofarm is a U.S.-based distributor, designer and marketer of a comprehensive assortment of specialty indoor gardening supplies.

  • With 5,000+ SKUs, and 1,000+ proprietary SKUs the company offers one of the largest assortments of indoor gardening merchandise in North America

  • The company was founded in 1977 and is based in California with 250+ employees

Broadband Capital co-invested alongside Serruya Private Equity and Hawthorn Equity Partners in connection with a $220 million control buyout transaction

  • Investment vehicles controlled by Broadband Capital invested $25 million, representing ~28% of new equity

  • Principals of Broadband Capital represented ~20% of total investment vehicle equity.

Broadband Capital co-invested alongside Serruya Private Equity, Hawthorn Equity Partners in connection with a subsequent $55mm equity financing.

Broadband Capital identified and delivered the key management addition
  • William Toler as Chairman and CEO – Formerly CEO of Hostess Brands, AdvancePierre Foods and President of Pinnacle Foods

  • Terry Fitch as President – Formerly of Coca-Cola Company and Coke Enterprises

Montrose Environmental Group
Pre-IPO Financing for the Leading U.S. Air Quality Emissions Testing Firm

Montrose Environmental Group is a private, high-growth, provider of air quality and environmental laboratory services in the United States

BCM provided $40 million in aggregate financing

  • Pursue acquisition targets and achieve scale for contemplated IPO

  • $30 million in equity and $10 million in debt

Montrose is led by Vijay Manthripragada

  • Former CEO of PetCareRx and SVP, Goldman Sachs

Richard Perlman and Jim Price, entrepreneurs with significant industry consolidation experience, are members of the board

Montrose Environmental Group
Pre-IPO Financing Traditional IPO led by Bank of America

Montrose Environmental Group is the leading provider of air quality and environmental testing laboratory services in the United States

BCM provided $40 million in aggregate financing

  • Pursue acquisition targets and achieve scale for contemplated IPO

  • $30 million in equity and $10 million in debt

Montrose is led by Vijay Manthripragada

  • Former CEO of PetCareRx and SVP, Goldman Sachs

Richard Perlman and Jim Price, entrepreneurs with significant industry consolidation experience, including Examworks, are chairman and members of the board

ExamWorks (EXAM)
Pre-IPO Financing into Traditional IPO Led by Goldman Sachs

ExamWorks provides independent medical examinations, peer and bill reviews, and related services in the United States, Canada, the United Kingdom, and Australia

BCM provided $33mm in a private placement allowing the company to:

  • Acquire several targets

  • Achieve scale for traditional IPO

Within 12 months of the private placement:

  • Closed 16 acquisitions using cash and stock

  • Goldman Sachs led $190mm IPO

Acquired by Leonard Green and Partners and management for $2.2 billion in July 2016

ExamWorks (EXAM)
Pre-IPO Financing Traditional IPO Led by Goldman Sachs

ExamWorks provides independent medical examinations, peer and bill reviews and related services in the United States, Canada, the United Kingdom and Australia

Founders Richard Perlman (Co-Chairman and Co-CEO) and Jim Price (Co-Chairman and Co-CEO)

BCM provided $33mm in a private placement allowing the company to:

  • Acquire several targets

  • Achieve scale for traditional IPO

Within 12 months of the private placement:

  • Closed 16 acquisitions using cash and stock

  • Goldman Sachs led $190mm IPO

Acquired by Leonard Green and Partners and management for $2.2 billion in July 2016